Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial.

Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, Poppe A, Wildiers H, Dieudonné AS, Brouckaert O, Decloedt J, Berteloot P, Verhoeven D, Joerger M, Vuylsteke P, Wynendaele W, Casteels M, Van Huffel S, Lybaert W, Van Ginderachter J, Paridaens R, Vergote I, Dezentjé VO, Van Calster B, Guchelaar HJ.

Clin Cancer Res. 2018 May 15;24(10):2312-2318. doi: 10.1158/1078-0432.CCR-17-3028. Epub 2018 Feb 19.

PMID:
29459457
2.

The timing of surgery after neoadjuvant radiotherapy influences tumor dissemination in a preclinical model.

Leroi N, Sounni NE, Van Overmeire E, Blacher S, Marée R, Van Ginderachter J, Lallemand F, Lenaerts E, Coucke P, Noel A, Martinive P.

Oncotarget. 2015 Nov 3;6(34):36825-37. doi: 10.18632/oncotarget.5931.

3.

Polymeric nanoreactors for enzyme replacement therapy of MNGIE.

De Vocht C, Ranquin A, Van Ginderachter J, Vanhaecke T, Rogiers V, Van Gelder P, Versées W, Steyaert J.

J Control Release. 2010 Nov 20;148(1):e19-20. doi: 10.1016/j.jconrel.2010.07.011. No abstract available.

PMID:
21529599
4.

Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.

Van Calster B, Van Ginderachter J, Vlasselaer J, Van de Putte G, Berteloot P, Timmerman D, Depypere H, Blomme C, Vlaemynck G, De Jonge E, Van den Broecke R, Vergote I, Amant F, Van Huffel S, Neven P.

Menopause. 2011 Feb;18(2):224-9. doi: 10.1097/gme.0b013e3181eb9f14.

PMID:
20881891
5.

Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells.

Jongert E, Lemiere A, Van Ginderachter J, De Craeye S, Huygen K, D'Souza S.

Vaccine. 2010 Mar 16;28(13):2556-64. doi: 10.1016/j.vaccine.2010.01.031. Epub 2010 Jan 29.

PMID:
20117266
6.

Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26-28, 2006.

Neven P, Vergote I, Amant F, Berteloot P, de Jonge E, DE Rop C, DE Sutter P, Makar A, VAN Ginderachter J.

Int J Gynecol Cancer. 2006;16 Suppl 2:479-91. No abstract available.

PMID:
17010051
7.

Endocrine treatment and prevention of breast and gynaecological cancers.

Neven P, Vergote I, Van Ginderachter J, van Dam P, Tjalma W, De Rop C, De Prins F.

Eur J Cancer. 2002 Nov;38 Suppl 6:S1-11. No abstract available.

PMID:
12409056
8.

Multiple effects of transfection with interleukin 2 and/or interferon gamma on the behavior of mouse T lymphoma cells.

Geldhof AB, Van Ginderachter J, Vandersteen P, Raes G, De Baetselier P.

Clin Exp Metastasis. 1998 Jul;16(5):447-59.

PMID:
10091940
9.

Effects of altered antigen processing on H-2Dk mediated NK inhibition in a murine T lymphoma model.

Van Ginderachter J, Raes G, Devoogdt N, De Baetselier F, Geldhof A.

Adv Exp Med Biol. 1998;451:237-40. No abstract available.

PMID:
10026878
10.

Effects of altered antigen processing on T-cell responses toward murine T-lymphomas.

Raes G, Van Ginderachter J, Devoogdt N, Geldhof A, De Baetselier P.

Adv Exp Med Biol. 1998;451:211-5. No abstract available.

PMID:
10026874
11.

Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model.

Raes G, Van Ginderachter J, Liu YQ, Brys L, Thielemans K, De Baetselier P, Geldhof A.

Cancer Immunol Immunother. 1998 Jan;45(5):257-65.

PMID:
9439649

Supplemental Content

Loading ...
Support Center